复方苦参注射液配合GEMOX方案治疗中晚期胰腺癌50例疗效观察

发布时间：2018-03-23 06:38

本文选题：胰腺癌　切入点：复方苦参注射液　出处：《辽宁中医杂志》2017年12期 　论文类型：期刊论文

【摘要】：目的:分析复方苦参注射液配合GEMOX方案治疗中晚期胰腺癌的临床疗效,旨意为相关研究工作提供参考资料。方法:择取2009年3月—2015年11月本院收治的50例中晚期胰腺癌者为研究样本,依照就诊顺序,分为观察组以及对照组,每组50例。对照组行GEMOX方案,以此为基础,观察组使用复方苦参注射液。分析临床效果。结果:两组病患治疗有效率无显著差异(P0.05)。与对照组相比,观察组稳定率更高(P0.05)。治疗前,两组患者的肿瘤标记物无明显差异(P0.05)。治疗后,病患肿瘤标记物均有改善,与对照组治疗后相比,观察组CEA以及CA19-9标记物变化更为显著(P0.05)。治疗前,两组患者的临床症状评分无明显差异(P0.05)。治疗后,病患相关指标改善,与对照组治疗后相比,观察组改善幅度更大(P0.05)。治疗前,两组患者KPS分数无明显差异(P0.05)。治疗后,与对照组相比,观察组KPS分数更高(P0.05)。结论:对于中晚期胰腺癌病患,以复方苦参注射液配合GEMOX方案治疗,临床效果显著,安全性强,可在一定程度上改善病患生活质量,延长无症状生存期,值得进一步推广使用。
[Abstract]:Objective: to analyze the clinical effect of compound Sophora flavescens injection combined with GEMOX regimen in the treatment of advanced pancreatic cancer. Methods: 50 patients with advanced pancreatic cancer admitted in our hospital from March 2009 to November 2015 were selected as study samples and divided into observation group and control group according to the order of visit. 50 patients in each group were treated with GEMOX regimen, and the observation group was treated with compound Sophora flavescens injection. Results: there was no significant difference in the effective rate of treatment between the two groups (P 0.05). Compared with the control group, the stability rate of the observation group was higher than that of the control group. Before treatment, the stable rate of the observation group was higher than that of the control group. There was no significant difference in tumor markers between the two groups (P 0.05). After treatment, the tumor markers were improved. Compared with the control group, the changes of CEA and CA19-9 markers in the observation group were more significant than those in the control group (P 0.05). There was no significant difference in the clinical symptom scores between the two groups (P 0.05). After treatment, the related indexes of the patients were improved. Compared with the control group, the improvement was greater in the observation group than in the control group. Before treatment, there was no significant difference in KPS scores between the two groups (P 0.05). After treatment, there was no significant difference in KPS scores between the two groups. Compared with the control group, the KPS score of the observation group was higher than that of the control group (P 0.05). Conclusion: for the patients with advanced pancreatic cancer, the treatment with compound Sophora flavescens injection combined with GEMOX regimen is effective and safe, and can improve the quality of life of the patients to some extent. Prolonging the asymptomatic survival time is worth further popularizing.
【作者单位】：解放军251医院;通辽市医院;
【分类号】：R735.9

【相似文献】